TPP Alberta

TPP Alberta is about using data to optimize safe patient care. Since 1986, we have been monitoring the use of prescription drugs prone to misuse in the province.

How to register as a prescriber with TPP Alberta

  • Prescribers must register with TPP Alberta to order their first TPP prescription pad and prescribe any Type 1 medications monitored by the program.
  • Type 2 medications do not have special prescribing requirements, but are monitored through Netcare, Pharmaceutical Information Network (PIN).
  • Medical residents must obtain approval from their program director prior to registering with TPP Alberta.
  • Following registration, you will receive a personalized TPP Alberta pad. See our guide on how to use the TPP Alberta secure 2-part form.

How to re-order a TPP Alberta prescription pad

Please note due to the COVID-19 pandemic, TPP Alberta is not accepting re-order requests via regular mail until further notice.

Complete and submit this form to re-order your TPP Alberta prescription pad

Prescribers with TPP Alberta prescribing restrictions

Based on data from TPP Alberta, CPSA can impose prescribing conditions on physicians that restrict their prescriptive authority under certain situations. These listings and conditions are in the accordion below.

Pharmacists can contact TPP Alberta using the contact form at the bottom of this page for guidance if questions arise or advice is required in specific circumstances.

List of prescribers with restrictions

Surname Given Name Date Effective Restrictions
Adams Jim Nov. 1, 2020 Type 1 and Type 2 medications monitored by TPP Alberta except for methylphenidate, benzodiazepines and Z class drugs.
Akinjise Idowu Jan. 13, 2019 Restricted from prescribing medications monitored by TPP Alberta, including cannabinoids and methadone, except for hospital inpatients.
Beeharry Raj Sept. 1, 2017 Restricted from prescribing any benzodiazepines, including chloral hydrate, zopiclone and other z-drugs unless the prescription is: a. Prescribed as an anticonvulsant; b. Prescribed to a patient for a maximum of two weeks in any three month period; or c. Supported by written direction or recommendation from a consult from a specialist or knowledgeable colleague. Restricted from prescribing narcotic analgesics (or any products containing Codeine) unless the prescription is: a. A narcotic analgesic prescribed to a patient with malignancy-related pain that is documented by a pathology report or consultant’s report; b. A narcotic analgesic prescribed to a patient with acute, non-malignant pain for a maximum of two weeks for any three-month period; or c. Supported by written direction or recommendation from a consult from a specialist or knowledgeable colleague
Collett Franklin Dean Nov. 29, 2019 Prescribing restrictions for the following medications: Triplicate Prescription Program medications, anabolic steroids, methylphenidate, barbiturates, codeine containing drugs, amphetamine or amphetamine like appetite suppressants, benzodiazepines and other anxiolytics, hypnotics and sedatives, and muscle relaxants.
Datar Sunil June 23, 2016 Shall not prescribe, dispense or provide samples of any drug that is listed on the College’s Triplicate Prescription Program Product List, whether prescribed using the triplicate pad or otherwise monitored by the program, inclusive of codeine products, benzodiazepines and “Z Class Drugs”.
Dulai Gurjeet Singh March 27, 2020 Restricted from prescribing TPP Alberta (Type 1) medications except for hospital inpatients, patients in a long-term care facility and immediate administration in the emergency department. Restricted from dispensing or administering TPP Alberta (Type 2) medications.
Hauptman Robert Oct. 23, 2019 All TPP Alberta medications, with the exclusion of stimulants.
Jackman Kevin F.M. July 1, 2018 Restricted from prescribing any benzodiazepines and other anxiolytics, hypnotics and sedatives including chloral hydrate, zopiclone and other z-drugs with the following exceptions: prescribed as an anticonvulsant. Restricted from prescribing any drugs on the Triplicate Prescription Program Product List (and no products containing Codeine or tramadol) with the following exceptions: Narcotic analgesics for patients with malignancy-related pain that is documented by a pathology report or consultant’s report and non-TPP Narcotic analgesics (Codeine or Tramadol) for patients with acute non-malignant pain for a maximum of one week for each patient in any three month period.
Kim Sirim Aug. 9, 2018 Restricted from prescribing any medications on the Triplicate Medication List.
Kordyban Michael Dec. 2, 2015 Voluntarily surrenders all triplicate prescription pads under his control and shall not request resumption of prescribing of medications requiring the use of a triplicate prescription pad, in any manner.
Lavallee Melvyn November 5, 2020 Restricted from prescribing all medications monitored by TPP Alberta with the exception of antibiotics and sustained released stimulant medication with a documented diagnosis of attention deficit disorder.
Leivo Ray May 24, 2018 Restricted from prescribing medications monitored by the Triplicate Prescription Program, or tramadol products.
Lopez Roehl March 8, 2018 Restricted from prescribing Tramadol and any other medication on the Triplicate Prescription Program Medication List (Type 1 and Type 2 medications).
McAlpine Brian Douglas Feb. 14, 2012 Restricted from prescribing triplicate medications.Restricted from prescribing stimulant medications or medications used in the treatment of Attention Deficit Disorder.
McMahon Alan April 22, 2020 Restricted from prescribing TPP Alberta Type 1, Type 2 (not including antibiotics) and all cannabinoids.
McPeak Brian K. Aug. 28, 2019 Prescribing of Type 1 TPP Alberta medications restricted to inpatient facilities.
Mentz Helena Johanna Aug. 8, 2018 Restricted from prescribing tramadol, cannabinoids and all other medications on or monitored by the Triplicate Prescription Program Medication List (Type 1 and Type 2 medications).
Mohamed Ataher S Nov. 21, 2016 Restricted from prescribing any medication monitored by the Triplicate Prescription Program.
Moir James Allan May 12, 2017 Restricted from prescribing medications designated as part of the Triplicate Prescription Program.
Nakashima Brenda Akemi April 22, 2020 Restricted from prescribing benzodiazepines and benzodiazepine-like drugs (Z drugs) monitored by TPP Alberta except to patients for immediate administration in the Emergency Department, or dispensing from the Emergency Department for patients being discharged.
Neu S. Randall Dec. 16, 2018 Restricted from prescribing triplicate medication.
Rosenstock Carl July 1, 2017 Restricted from prescribing any benzodiazepines, including chloral hydrate, zopiclone and other z-drugs with the following exceptions: 1. Prescribed as an anticonvulsant; 2. Prescribed to a patient for a maximum of two weeks in any three month period; or 3. Supported by a direction or recommendation arising from a consult from a specialist or knowledgeable colleague. Restricted from prescribing any drugs on the Triplicate Prescription Program List (or any products containing Codeine) with the following exceptions: 1. A narcotic analgesic prescribed to a patient with malignancy-related pain that is documented by a pathology report or consultant’s report; 2. A narcotic analgesic prescribed to a patient with acute non-malignant pain for a maximum of two weeks for any three month period; or 3. Supported by a direction or recommendation arising from a consult from a specialist or knowledgeable colleague.
Swart Johan Dec. 14, 2017 Restricted from prescribing Tramadol products or medications on either of the schedules of the Triplicate Prescribing Program.
Thompson Robert Douglas July 4, 2013 Restricted from prescribing any medications which require a Triplicate Prescription pad.
Warneke Lorne Feb. 4, 2019 Restricted from prescribing any triplicate medications and any stimulant medication including Dexedrine, Concerta, and Biphentin.
Werkman Isabella March 1, 2020 Restricted from prescribing opioid medications, methadone, Suboxone and cannabinoids.

Any prescribing condition effective before March 1st, 2021 does not include Antibiotics.

TPP Alberta FAQs for prescribers

All FAQs

Can TPP Alberta prescriptions be faxed to the pharmacist?

Yes, if the program’s secure 2-part form is used.

Please refer to CPSA’s Prescribing: Administration standard of practice and advice document for more information.

Do I need to register with TPP Alberta in order to prescribe buprenorphine/naloxone?

No. As of July 2019, when buprenorphine/naloxone was changed to Type 2 TPP Alberta status, registration with the Program was no longer required.  Use of the secure TPP Alberta secure form is no longer required when prescribing buprenorphine/naloxone combination products.  Single-entity buprenorphine products continue to be  TPP Type 1 category so registration with TPP Alberta and use of the secure pad are required.

Do I need to register with TPP Alberta in order to prescribe other Opiate Agonist Therapies (OATs), such as methadone?

Yes. Registration with TPP Alberta and use of the secure TPP Alberta prescription form is required when prescribing methadone and other OATs.

How long do I retain my copy of the TPP Alberta form?

The TPP Alberta secure form is considered part of the patient record. A copy should be retained for the same period that a patient record must be maintained as per applicable legislation for your profession.

How will my TPP pad be delivered?

TPP pads are delivered by Purolator and someone must be available to sign for the parcel. Please note that we cannot accept out of province or PO Box addresses for deliveries.

I am moving my practice. Does the TPP Alberta pad stay at my old clinic?

Your TPP Alberta pad is issued to you as a prescriber. If you are moving your practice, you should take your pad with you and update TPP Alberta by emailing TPP.Info@cpsa.ab.ca, calling 780-969-4939 or 1-800-561-3899 ext. 4939 (toll free), or faxing 780-429-1981.

Is cannabis for medical purposes monitored by TPP Alberta?

TPP Alberta collects data on cannabis for medical purposes for CPSA’s Cannabis for Medical Purposes Program.

Physicians are required to submit the Patient Medical Document to CPSA within 7 days of its completion.

Is diphenoxylate a monitored drug for veterinary practices?

No, dipehnoxylate is not monitored by TPP Alberta. Veterinary practices do not need to report prescribing for diphenoxylate (brand name: Lomotil).

These scripts do not need to be sent in for manual data entry. For details, please contact ABVMA.

What can I do if my secure forms are lost or stolen?

Prescribers must notify police and TPP Alberta immediately. You can contact us at: TPPInfo@cpsa.ab.ca or 1-800-561-3899, ext. 4939

The prescriber should provide the following information to TPP Alberta:

  • Prescriber contact information and registration number
  • Date of loss or theft
  • Tracking numbers of missing forms
  • Name of the last patient prescribed a secure prescription
  • The police file number and the investigating constable’s name and phone number

While this is not required, we encourage including details on circumstances related to the incident. Where available, this information is used in a de-identified format to inform guidance from TPP Alberta.

When can I expect to receive my TPP pad?

If you are already registered for TPP Alberta, it can take up to 10 business days to receive your order.

If you are not yet registered for the program, please allow additional time for your registration to be processed. It can take up to 15 business days from the date your registration form is received for your first pad to be delivered. You will receive a welcome letter and information package once your registration has been processed and your first pad has been ordered.

If you have questions about the status of your order or registration, please contact TPP Alberta by email at TPPinfo@cpsa.ab.ca or phone at 1-800-561-3899 ext. 4939.

Where should I keep the prescriber’s copy of the TPP Alberta form?

You should keep the PRESCRIBER COPY (bottom copy) of the 2-part secure form within the patient’s record at your clinic. Refrain from leaving the form within the pad. Storing the copy within the pad can compromise patient confidentiality, especially in the case of loss or theft.

Why are Biphentin, Concerta and Foquest Type 2 TPP drugs and other methylphenidate products Type 1?

The manufacturers of Biphentin, Concerta and Foquest provided TPP Alberta with detailed information on the tamper-resistant properties of these products. Similar information has not been provided for the methylphenidate products in the Type 1 category.

FAQs for pharmacists

All FAQs

Do I need to send a copy of the secure form to TPP Alberta?

Dispensers of TPP medications send the forms to TPP Alberta at least twice a month for data entry, if the scripts meet these criteria:

  • compounded medications
  • office use
  • veterinary use

Information for other tracked prescriptions is sent to TPP Alberta via Netcare/PIN. However, pharmacies should keep a copy in case TPP Alberta requests access to it.

How do I know if a prescriber has a restriction around prescribing TPP Alberta monitored medications?

Please refer to the Prescribers With TPP Alberta Prescribing Restrictions list.

Is there a list of stolen and missing TPP Alberta forms?

Pharmacists looking for the list of stolen or missing TPP Alberta scripts can access the list through the Alberta College of Pharmacy (login required).

Why are Biphentin, Concerta and Foquest Type 2 TPP drugs and other methylphenidate products Type 1?

The manufacturers of Biphentin, Concerta and Foquest provided TPP Alberta with detailed information on the tamper-resistant properties of these products. Similar information has not been provided for the methylphenidate products in the Type 1 category.

FAQs for Albertans

All FAQs

How do I know if my health care provider can prescribe TPP Alberta monitored medications?

Patients are entitled to ask their health care provider if they prescribe medications monitored by TPP Alberta.

What is "multi doctoring"?

“Multi-doctoring” is when a patient visits multiple health care providers to obtain multiple prescriptions, within a 30 day period, without informing the prescribers about every prescription or narcotic obtained.

Both unlawful possession and obtaining multiple prescriptions for opioids and some other prescription drugs, without proper disclosure, are criminal offences that can bring a fine of up to $1,000 or imprisonment for up to six months, or both, for a first offence (summary conviction). Penalties increase for subsequent convictions or possession of larger amounts. For example, conviction for trafficking can bring life imprisonment. For more information, refer to the Controlled Drugs and Substances Act, (1996, c. 19 C-38.8)

Prescribers can access information on a patient’s prescription history via Alberta Netcare’s Pharmaceutical Information Network (PIN). TPP Alberta can also be contacted for a patient’s TPP profile.

When will my cannabis be delivered?

TPP Alberta is not responsible for the delivery of prescription cannabis. Please talk to your prescriber for more information on your cannabis prescription.

Will TPP Alberta provide a list of health care providers who prescribe specific drugs on the TPP Alberta medications list, such as methadone, cannabis or narcotics?

No.

TPP Alberta Partners

TPP Alberta is funded primarily by the provincial government and administered by CPSA. TPP Alberta partners are:

Alberta Health logo Alberta College of PharmacyAlberta Dental Association & College logo Alberta Medical Association logoAlberta Pharmacists' Association logoCollege & Association of Registered Nurses of Alberta logo College of Podiatric Physicians of Alberta logo       CPSA logo

Questions about TPP Alberta?

Toll-free: 1-800-561-3899